Inhibikase Therapeutics up 19% after FDA lifts full clinical hold

Inhibikase shares are up 14c, or 19%, to 84c in pre-market trading after the company announced the U.S. FDA has lifted the full clinical hold on IkT-148009, the company’s c-Abl inhibitor, in Multiple System Atrophy, or MSA, allowing the company to proceed with its plans for a future Phase 2 clinical trial in MSA.